JP2023531594A - 抗体結合ナノ粒子 - Google Patents

抗体結合ナノ粒子 Download PDF

Info

Publication number
JP2023531594A
JP2023531594A JP2022575309A JP2022575309A JP2023531594A JP 2023531594 A JP2023531594 A JP 2023531594A JP 2022575309 A JP2022575309 A JP 2022575309A JP 2022575309 A JP2022575309 A JP 2022575309A JP 2023531594 A JP2023531594 A JP 2023531594A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
nos
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531594A5 (enExample
Inventor
ウエダ，ジョージ
ラザロヴィッツ，ジェームズ
ファラス，ジョージ
ベイカー，デイビッド
ルオホラ－ベイカー，ハンネレ
ディヴァイン，ロバート
チャオ，ヤン（ブレア），ティン
マチュー，ジュリー
キング，ニール，ピー．
トゥーリー，マルティ，レイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2023531594A publication Critical patent/JP2023531594A/ja
Publication of JP2023531594A5 publication Critical patent/JP2023531594A5/ja
Priority to JP2026029727A priority Critical patent/JP2026102638A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022575309A 2020-06-08 2021-06-07 抗体結合ナノ粒子 Pending JP2023531594A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026029727A JP2026102638A (ja) 2020-06-08 2026-02-26 抗体結合ナノ粒子

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063036062P 2020-06-08 2020-06-08
US63/036,062 2020-06-08
US202063085351P 2020-09-30 2020-09-30
US63/085,351 2020-09-30
US202063088586P 2020-10-07 2020-10-07
US202063088576P 2020-10-07 2020-10-07
US63/088,576 2020-10-07
US63/088,586 2020-10-07
PCT/US2021/036117 WO2021252327A2 (en) 2020-06-08 2021-06-07 Antibody-bound nanoparticles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026029727A Division JP2026102638A (ja) 2020-06-08 2026-02-26 抗体結合ナノ粒子

Publications (2)

Publication Number Publication Date
JP2023531594A true JP2023531594A (ja) 2023-07-25
JP2023531594A5 JP2023531594A5 (enExample) 2024-07-23

Family

ID=76971985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022575309A Pending JP2023531594A (ja) 2020-06-08 2021-06-07 抗体結合ナノ粒子
JP2026029727A Pending JP2026102638A (ja) 2020-06-08 2026-02-26 抗体結合ナノ粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026029727A Pending JP2026102638A (ja) 2020-06-08 2026-02-26 抗体結合ナノ粒子

Country Status (7)

Country Link
US (1) US20230233707A1 (enExample)
EP (1) EP4161655A2 (enExample)
JP (2) JP2023531594A (enExample)
CN (1) CN116113401A (enExample)
AU (1) AU2021286457A1 (enExample)
CA (1) CA3180541A1 (enExample)
WO (1) WO2021252327A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026128573A1 (en) * 2024-12-12 2026-06-18 University Of Washington De novo designed tie2 mini binder acting as an agonist or antagonist for tie2 receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016010014A1 (ja) * 2014-07-15 2016-01-21 アステラス製薬株式会社 新規抗ヒトＴｉｅ２抗体
US20160058828A1 (en) * 2013-04-11 2016-03-03 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
US20180137234A1 (en) * 2016-11-16 2018-05-17 University Of Washington Computational Design of Self-Assembling Cyclic Protein Homo-oligomers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB2555131A (en) * 2016-10-20 2018-04-25 Imperial Innovations Ltd Nanocage
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160058828A1 (en) * 2013-04-11 2016-03-03 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
WO2016010014A1 (ja) * 2014-07-15 2016-01-21 アステラス製薬株式会社 新規抗ヒトＴｉｅ２抗体
US20180137234A1 (en) * 2016-11-16 2018-05-17 University Of Washington Computational Design of Self-Assembling Cyclic Protein Homo-oligomers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOMATERIALS, vol. VOL:33, NR:21, JPN5023010192, 15 March 2012 (2012-03-15), pages 5423 - 5430, ISSN: 0005822151 *
CELL, vol. VOL:176, NR:6, JPN5023010195, March 2019 (2019-03-01), pages 1420 - 1431, ISSN: 0005671999 *
JOURNAL OF CONTROLLED RELEASE, vol. 249, JPN5023010194, 7 January 2017 (2017-01-07), pages 1 - 10, ISSN: 0005671998 *
RSC ADVANCES, vol. VOL:6, NR:23, JPN5023010193, 2016, pages 19208 - 19213, ISSN: 0005822152 *

Also Published As

Publication number Publication date
JP2026102638A (ja) 2026-06-23
AU2021286457A1 (en) 2023-01-05
US20230233707A1 (en) 2023-07-27
CA3180541A1 (en) 2021-12-16
WO2021252327A3 (en) 2022-02-17
EP4161655A2 (en) 2023-04-12
WO2021252327A2 (en) 2021-12-16
CN116113401A (zh) 2023-05-12

Similar Documents

Publication Publication Date Title
TWI250988B (en) Thrombopoietic compounds
Leong et al. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation
CN107011425B (zh) 抑制vegf-a受体相互作用的结合蛋白
KR101658247B1 (ko) 모듈 인식 도메인을 통한 항체 표적화
RS51852B (sr) Modifikovani peptidi kao terapeutski agensi
EP4048302A1 (en) Methods of administration of il-2 receptor agonists
CN116675777B (zh) 包含补体抑制结构域的多特异性配体结合分子及其用途
JP2023531594A5 (enExample)
EP4438629A1 (en) Multispecific ligand binding molecule and application thereof
EP4161655A2 (en) Antibody-bound nanoparticles
CN116162148B (zh) 多特异性配体结合分子及其应用
CN102470157B (zh) 广谱erbb配体结合分子及其制备和使用方法
CN115666522B (zh) 包含il-2蛋白和cd80蛋白的融合蛋白制剂
JP2023528651A (ja) 設計抗体結合ナノ粒子
CN112194728B (zh) 用于内毒素清除的嵌合抗原受体及其应用
CA3220239A1 (en) A super-trail molecule comprising two trail trimers
CN104640557A (zh) 骨保护素衍生的组合物及其用途
HK40101761A (en) A super-trail molecule comprising two trail trimers
US20230322882A1 (en) Fusion Polypeptide and Polypeptide Dimer, and Use Thereof
US7579316B2 (en) Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
HK40116769A (en) Multispecific ligand binding molecule and application thereof
HK40092774A (en) Methods of using activin receptor type ii variants
CN118510812A (zh) 基于sirp1a和cd40l的嵌合蛋白
HK1238258A1 (en) Binding proteins inhibiting the vegf-a receptor interaction
HK1161726A (en) Binding proteins inhibiting the vegf-a receptor interaction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324